The <em>PI3K</em> inhibitor GDC-0941 is synergistic with lapatinib and mediates endocrine sensitivity in uterine papillary serous carcinoma via AKT

Hou, June

274 - Poster Session A
The PI3K inhibitor GDC-0941 is synergistic with lapatinib and mediates endocrine sensitivity in uterine papillary serous carcinoma via AKT

Saturday, March 22, 2014: 6:45 AM

West Exhibit Hall (Tampa Convention Center)

K. Levano¹, A. G. Rodriguez-Gabin², Y. Wang³, M. H. Einstein³, G. L. Goldberg³, S. B. Horwitz² and J. Y. Hou³
¹Peruvian National Institute of Health, Lima 9, Peru, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

274 - Poster Session A
The PI3K inhibitor GDC-0941 is synergistic with lapatinib and mediates endocrine sensitivity in uterine papillary serous carcinoma via AKT

274 - Poster Session A The PI3K inhibitor GDC-0941 is synergistic with lapatinib and mediates endocrine sensitivity in uterine papillary serous carcinoma via AKT

274 - Poster Session A
The PI3K inhibitor GDC-0941 is synergistic with lapatinib and mediates endocrine sensitivity in uterine papillary serous carcinoma via AKT